Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial
Authors

Marie Warrent Munch1,2, Tine Sylvest Meyhoff1,2, Marie Helleberg3, Maj-Britt Nørregaard Kjær1,2, Anders Granholm1,2, Carl Johan Steensen Hjortsø1,2, Thomas Steen Jensen1,2, Morten Hylander Møller1,2, Peter Buhl Hjortrup1,2, Mik Wetterslev1,2, Gitte Kingo Vesterlund1,2, Lene Russell1,2, Vibeke Lind Jørgensen4, Klaus Tjelle Kristiansen5, Thomas Benfield6, Charlotte Suppli Ulrik7, Anne Sofie Andreasen8, Morten Heiberg Bestle2,9,10, Lone Musaeus Poulsen11, Thomas Hildebrandt12, Lene Surland Knudsen13, Anders Møller14, Christoffer Grant Sølling15, Anne Craveiro Brøchner16, Bodil Steen Rasmussen2,17, Henrik Nielsen18, Steffen Christensen19, Thomas Strøm20, Maria Cronhjort21, Rebecka Rubenson Wahlin21, Stephan M. Jakob21, Luca Cioccari22, Balasubramanian Venkatesh23,24, Naomi Hammond23 Vivekanand Jha24,25,26, Sheila Nainan Myatra27, Marie Qvist Jensen7, Jens Wolfgang Leistner1, Vibe Sommer Mikkelsen1, Jens S. Svenningsen1, Signe Bjørn Laursen1, Emma Victoria Hatley1, Camilla Meno Kristensen1, Ali Al-Alak6, Esben Clapp6, Trine Bak Jonassen6, Caroline Løkke Bjerregaard9, Niels Christian Haubjerg Østerby9, Mette Mindedahl Jespersen9, Dalia Abou-Kassem8, Mathilde Languille Lassen8, Reem Zaabalawi14, Mohammed Mahmoud Daoud14, Suheyb Abdi14, Nick Meier1, Kirstine la Cour11, Cecilie Bauer Derby11, Birka Ravnholt Damlund11, Jens Laigaard11, Lene Lund Andersen16, Johan Mikkelsen16, Jeppe Lundholm Støarfeld Jensen16, Anders Hørby Rasmussen15, Emil Arnerlöv25, Mathilde Lykke15, Mikkel Zacharias Bystrup Holst-Hansen19, Boris Wied Tøstesen19, Janne Schwab19,28, Emilie Kabel Madsen19, Christian Gluud29,30, Theis Lange31, Anders Perner1,2

1 Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
2 Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark
3 Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
4 Department of Thoracic Anaesthesiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
5 Department of Anaesthesia and Intensive Care, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark
6 Center of Research & Disruption of Infectious Diseases, Department of Infectious Diseases, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark
7 Department of Respiratory Medicine, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark
8 Department of Anaesthesia and Intensive Care, Herlev Hospital, University of Copenhagen, Denmark

This article is protected by copyright. All rights reserved
9 Department of Anaesthesia and Intensive Care, Copenhagen University Hospital, North Zealand, Denmark
10 Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
11 Department of Anaesthesiology, Zealand University Hospital, Køge, Denmark
12 Department of Anaesthesia and Intensive Care, Zealand University Hospital, Roskilde, Denmark
13 Department of Infectious Diseases, Zealand University Hospital, Roskilde, Denmark
14 Department of Anaesthesia and Intensive Care Næstved-Slagelse-Ringsted Hospital, Slagelse, Denmark
15 Department of Anaesthesia and Intensive Care, Viborg Hospital, Denmark
16 Department of Anaesthesia and Intensive Care, Kolding Hospital, Denmark
17 Department of Anaesthesia and Intensive Care, Aalborg University Hospital, Denmark
18 Department of Infectious diseases, Aalborg University Hospital, Denmark
19 Department of Anaesthesiology and Intensive Care, Aarhus University Hospital, Denmark
20 Department of Anaesthesia and Intensive Care, Odense University Hospital, Denmark
21 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden
22 Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland
23 The George Institute for Global Health, University of New South Wales, Australia
24 The George Institute for Global Health, University of New South Wales, New Delhi, India
25 Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India
26 School of Public Health, Imperial College London, United Kingdom
27 Department of Anaesthesia, Critical Care and Pain, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
28 Flavour Institute, Aarhus University, Aarhus, Denmark
29 Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
30 Department of Regional Health Research, Faculty of Health Sciences, The University of Southern Denmark, Odense, Denmark
31 Department of Public Health, Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark

Corresponding author

This article is protected by copyright. All rights reserved
Marie Warrer Munch, Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Contact details
marie.warrer.munch@regionh.dk
Tel.: +4535457237

Trial registration
ClinicalTrials.gov: NCT04348305
European Union Drug Regulation Authorities Clinical Trials (EudraCT) Database: 2020-001395-15

Funding sources
Funded by the Novo Nordisk Foundation, Grant/Award Number: 0062998 and supported by Rigshospitalet's Research Council, Grant/Award Number: E-22703-06 and Pfizer, Grant/Award Number: 60473019. The funding sources were not involved in designing, conducting, analysing or reporting of the COVID STEROID trial.

Word count
2.645 excluding abstract, acknowledgements and conflict of interest declaration.
Abstract

Background
In the early phase of the pandemic, some guidelines recommended the use of corticosteroids for critically ill patients with COVID-19, whereas others recommended against the use despite lack of firm evidence of either benefit or harm. In the COVID STEROID trial, we aimed to assess the effects of low-dose hydrocortisone on patient-centred outcomes in adults with COVID-19 and severe hypoxia.

Methods
In this multicentre, parallel-group, placebo-controlled, blinded, centrally randomised, stratified clinical trial, we randomly assigned adults with confirmed COVID-19 and severe hypoxia (use of mechanical ventilation or supplementary oxygen with a flow of at least 10 L/min) to either hydrocortisone (200 mg/day) versus a matching placebo for 7 days or until hospital discharge. The primary outcome was the number of days alive without life support at day 28 after randomisation.

Results
The trial was terminated early when 30 out of 1,000 participants had been enrolled because of external evidence indicating benefit from corticosteroids in severe COVID-19. At day 28, the median number of days alive without life support in the hydrocortisone versus placebo group were 7 versus 10 (adjusted mean difference: -1.1 days, 95% CI -9.5 to 7.3, p = 0.79); mortality was 6/16 versus 2/14; and the number of serious adverse reactions 1/16 versus 0/14.

Conclusions
In this trial of adults with COVID-19 and severe hypoxia, we were unable to provide precise estimates of the benefits and harms of hydrocortisone as compared with placebo as only 3% of the planned sample size were enrolled.
Editorial Comment

In this trial, the authors aimed to assess the effects of low-dose hydrocortisone on patient-centered outcomes in adults with COVID-19 and severe hypoxia. The trial was terminated very quickly after starting enrollment, due to unexpected (at trial design) inability to enroll participants. Despite this, the final trial disposition is interesting to note as an example of the challenges for studying important treatments in the setting of very rapidly-changing treatment recommendation changes during the pandemic.

Keywords

COVID-19, SARS-CoV-2, Randomised clinical trial, Placebo-controlled trial, Corticosteroids, Hydrocortisone
Introduction

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may cause coronavirus disease 2019 (COVID-19), the clinical presentation of which varies from mild upper respiratory infection to severe acute respiratory distress syndrome (ARDS).

Systemic corticosteroids have been reported to benefit some patients with ARDS and septic shock. In the early phases of the COVID-19 pandemic, there were conflicting guidelines on the use of corticosteroids for COVID-19: the Surviving Sepsis Campaign advocated its use in critically ill patients with COVID-19 whilst the World Health Organization (WHO) initially recommended against it. To address this uncertainty, several clinical trials were initiated.

On April 15, 2020, we commenced the ‘Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial’ aiming to assess the effects of low-dose hydrocortisone versus placebo on patient-centred outcomes. We hypothesised that low-dose hydrocortisone would increase the number of days alive without life support as compared with placebo.

On June 16, 2020, enrolment was paused when 30 participants had been randomised because of a press release from the Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial reporting benefit from systemic corticosteroids on 28-day mortality in hospitalised patients with COVID-19. The Management Committee of the COVID STEROID trial decided to terminate the trial on September 4, 2020, due to the results from a WHO-initiated prospective meta-analysis (PMA) of ongoing or recently completed trials demonstrating benefit from systemic corticosteroids on 28-day mortality in critically ill patients with COVID-19, which in turn led to an update in the guideline from the WHO strongly recommending the use of systemic corticosteroids for patients with severe or critical COVID-19.

We provided data on 28-day mortality and serious adverse reactions (SARs) for 29 out of 30 trial participants to the PMA published in September 2020, because of the importance of summarising the evidence from all trials assessing corticosteroids in patients with critical COVID-19.

Here, we present the full trial report of the COVID STEROID trial, including 90-day follow-up.
Methods

Trial design

The COVID STEROID trial was an investigator-initiated, multicentre, parallel-group, placebo-controlled, blinded, centrally randomised, stratified clinical trial. We planned to randomise 1,000 adult patients with COVID-19 and severe hypoxia in Denmark, Sweden, Switzerland and India. The trial was commenced on April 15, 2020; paused on June 16, 2020; and terminated early on September 4, 2020, after 30 patients had been enrolled at 12 trial sites in Denmark.

Trial conduct

The COVID STEROID trial was conducted in accordance with the published trial protocol, the Helsinki Declaration in its latest version, the International Conference on Harmonization on Good-Clinical-Practice (GCP) guidelines, the General Data Protection Regulation and Danish laws. The trial results are reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement (Supplementary Information S1).

Patients were enrolled after obtaining deferred informed consent for temporary incompetent patients according to Danish law. The trial data and consents were monitored externally by the Good Clinical Practice (GCP) units of the participating regions in Denmark and centrally by staff from the coordinating centre.

Randomisation and allocation concealment

Patients fulfilling all inclusion criteria and no exclusion criteria were randomised in a 1:1 ratio to 200 mg of intravenous (IV) hydrocortisone versus placebo using a centralised and web-based randomisation system at the Copenhagen Trial Unit (CTU). The randomisation was performed according to a computer-generated allocation sequence, stratification variables (trial site, use of invasive mechanical ventilation (y/n), age below 70 years (y/n)), and varying block sizes. The allocation sequence was only known by the data manager at the CTU.
Blinding

The Management Committee, investigators, trial site staff registering outcome data, trial statistician, clinical staff, relatives, and participants were all blinded to the allocation. Trial medication was prepared daily using shelf-medication by a dedicated team of unblinded trial site staff (medical students and/or research nurses and doctors). The unblinded trial site staff were not involved in the care of trial participants, outcome data entry, or statistical analyses.

For the analyses conducted in the present report, the trial statistician received a blinded dataset with the allocation coded as 0 or 1. Of note, due to the previous publication of data on 28-day mortality and SARs, it was possible to identify the groups 0 and 1 by referral to the PMA.²¹

Trial participants

We screened adult patients (18 years or above) with confirmed SARS-CoV-2 infection and severe hypoxia defined as use of either invasive mechanical ventilation, non-invasive ventilation, or continuous use of continuous positive airway pressure (CPAP) for hypoxia, or oxygen supplementation with an oxygen flow of at least 10 L/min independent of delivery system. Participants were enrolled at participating hospitals (intensive care units or wards for infectious or pulmonary diseases).

We excluded patients who fulfilled one or more exclusion criteria listed in the Supplementary Information S2. Detailed definitions of the inclusion and exclusion criteria are available from the published trial protocol.²³

Trial interventions

Trial participants received either IV hydrocortisone (200 mg per day) or a matching placebo (isotonic saline) for 7 days or until hospital discharge (whichever came first). The injections had identical appearances.

For patients allocated to hydrocortisone, the trial intervention was given either as a continuous infusion over 24 hours or as bolus injections every 6 hours (50 mg per bolus). For patients allocated to placebo, the trial intervention was given either as a continuous infusion over 24 hours or as bolus injections every 6 hours.
All other interventions were given at the discretion of the treating clinicians. The procedure for trial medication preparation was described in detail in the published trial protocol.23

Outcomes

Detailed definitions of primary and secondary outcomes are presented in the published trial protocol.23

Primary outcome

The primary outcome was days alive without the use of life support (i.e. invasive mechanical ventilation, circulatory support, or renal replacement therapy, including days in between intermittent renal replacement therapy) at day 28.

Secondary outcomes

The secondary outcomes were:

• Number of participants with one or more serious adverse reactions at day 14 defined as new episodes of septic shock, invasive fungal infection, clinically important gastrointestinal bleeding, or anaphylactic reaction.

• All-cause mortality at day 28.

• Days alive without life support at day 90.

• Days alive and out of hospital at day 90.

• All-cause mortality at day 90.

Statistical analyses

We estimated that 1,000 participants would be required to have 85% power to detect a 15% relative reduction in 28-day mortality combined with a 10% reduction in the days on life support among survivors. Baseline data were presented descriptively in each group and in total with medians with interquartile ranges (IQRs) for continuous variables and numbers with percentages for categorical variables. Because the final sample size was substantially smaller than planned, deviations from the pre-published statistical
analysis plan were necessary (details are presented in Supplementary Information S3). For continuous outcomes, results are presented as medians with IQRs in each group and adjusted mean differences with 95% confidence intervals (CIs). For binary outcomes, results are presented as numbers with percentages in each group and adjusted relative risks (RR) with 95% CIs as described previously. All analyses were done in the intention-to-treat (ITT) population defined as all randomised participants for whom there were consent to use data. We had no missing outcome data, and only missing data for baseline lactate in one participant; accordingly, neither multiple imputation nor best-worst/worst-best case analyses were conducted.

Primary outcome

The primary outcome was evaluated using a linear regression adjusted for invasive mechanical ventilation and age below 70 years. We were unable to adjust for site due to the reduced sample size. The primary analysis was supplemented by a Wilcoxon rank sum test. Descriptive data on the primary outcome are presented in 5 out of 6 pre-planned subgroups (Table 4).

Secondary outcomes

For all secondary binary outcomes, we employed unadjusted generalised linear models with log links and binomial error distributions (except for SARs due to only 1 event). These were supplemented by Fisher’s exact tests.

The secondary continuous outcomes were evaluated as the primary outcome using linear regressions adjusted for invasive mechanical ventilation and age below 70 years and were supplemented by Wilcoxon rank sum tests.

*Post hoc survey of trial site clinicians*

We conducted a *post hoc* fully anonymised survey to assess how clinical practice was influenced by the RECOVERY preprint. We surveyed the clinical preferences for corticosteroid use for COVID-19 among doctors working at planned COVID STEROID trial sites in India, Sweden, Switzerland and Denmark. Moreover, we asked site investigators to submit aggregate data from participating hospitals on the use of corticosteroids in the last 10 COVID-19 patients admitted in July 2020 after the RECOVERY preprint had been published.
Results

The trial was initiated on April 15, 2020, and the first participant was enrolled on April 17, 2020. On June
16, 2020, enrolment was paused after a total of 30 participants had been randomised. Of these, 16 were
allocated to hydrocortisone and 14 were allocated to placebo, and all completed follow-up of data at day
90 (Figure 1).

The baseline characteristics of the trial participants are presented in Table 1 and the trial medication
administration and protocol violations in Table 2. The trial participants received the trial intervention for a
median of 7 days (IQR 6-7 days) in both groups. A total of 3 trial participants (2 allocated to hydrocortisone
and 1 allocated to placebo) discontinued the trial intervention for the reasons presented in Figure 1. In the
hydrocortisone and placebo groups, 8 and 3 participants had major protocol violations (i.e. concomitant
use of open-label corticosteroids during the first 14 days after randomisation or less than 50% of planned
trial medication volume administered on any day in the intervention period).

Outcomes

The outcome data for the 2 groups are presented in Table 3.

There was no statistically significant difference in the days alive without life support at day 28 after
randomisation (the primary outcome) in patients allocated to hydrocortisone versus those allocated to
placebo (adjusted mean difference: -1.1 days, 95% CI -9.5 to 7.3, p = 0.79).

In total, there was 1 patient with one or more SARs in the trial (hydrocortisone: 1/16; placebo 0/14). There
were no statistically significant differences in all-cause mortality at 28 and 90 days (28 days: RR 2.63, 95% CI
0.74 to 16.03, p = 0.19; 90 days: RR 2.04, 95% CI 0.71 to 8.16, p = 0.22), in the days alive without life
support at day 90 (adjusted mean difference: -14.7 days, 95% CI -40.4 to 10.9, p = 0.25) or in the days alive
and out of hospital at day 90 (adjusted mean difference: -6.5 days, 95% CI -29.6 to 16.7, p = 0.57).

Post hoc survey of trial site clinicians

Some results of the survey have already been published elsewhere.27

A total of 278 doctors from Denmark (53%), India (40%), Sweden (4%) and Switzerland (3%) responded to
the survey on corticosteroid use in patients with COVID-19. The responders primarily worked in ICUs (56%)
or departments of anaesthesiology (21%) or infectious diseases (15%).

This article is protected by copyright. All rights reserved
Most responders would sometimes or always use steroids for patients with COVID-19 (86%; 250 responders), in particular for patients with severe COVID-19 requiring oxygen therapy with a flow of 10-30 L/min (66%; 249 responders), >30 L/min (66%; 249 responders) or non-invasive ventilation or continuous CPAP (68%; 249 responders) or for patients with critical COVID-19 requiring mechanical ventilation (76%; 249 responders) or with septic shock (56%; 249 responders). The preferred corticosteroids were dexamethasone (86%; 240 responders) and methylprednisolone (45%; 240 responders). The dose preference varied with 56% of 240 responders preferring a dose of 6 mg of dexamethasone or equivalent and 36% of 240 responders preferring doses higher than 6 mg of dexamethasone or equivalent.27 Most would enrol patients in a future trial comparing a higher vs. lower dose of dexamethasone, primarily into one comparing 12 mg vs. 6 mg of dexamethasone (55% of 237 responders).27

A total of 24 ICUs and 3 departments of infectious diseases provided aggregate data on corticosteroid use after the preprint publication of RECOVERY. Of these, 6 ICUs had not had any patients with COVID-19 admitted after the publication of RECOVERY. A median of 10% of patients (IQR 0-38%) had received corticosteroids before admission to the ICU and median of 100% (IQR 100-100%) had received corticosteroids during ICU admission. The median dose used for all locations was 10 (IQR 6-15) mg dexamethasone (or equivalent).
Discussion

In this investigator-initiated, multicentre, parallel-group, blinded, centrally randomised, stratified clinical trial, we were unable to provide any precise estimates on the benefits and harms of hydrocortisone versus placebo for any outcomes as only 3% of the planned sample size was enrolled. In our post hoc survey, we found that the dose preferences for corticosteroid use in COVID-19 varied among doctors and that most would enrol their patients into a trial comparing higher versus lower doses of dexamethasone.

Strengths

The strengths include all those of a multicentre randomised, placebo-controlled trial. The trial design was pragmatic allowing all other interventions to follow standard care, and only patient-centred outcomes were reported. The trial was monitored externally by local GCP units in Denmark, and we had no missing values for any assessed outcome. The trial was reported in accordance with the CONSORT statement.26

Limitations

During the planning and commencement of the COVID STEROID trial, the number of COVID-19 patients in Denmark decreased leading to an unexpected low recruitment throughout the inclusion period. The recruitment was also lowered due to enrolment in other interventional trials prohibiting co-enrolment (16% of all excluded patients).

The COVID STEROID trial was terminated early when only 3% of the planned sample size had been enrolled resulting in highly uncertain point estimates.28 Yet, we consider it important to publish data on all outcomes out of respect for the trial participants and to allow for data to be included in future meta-analyses.

The trial intervention was subject to protocol violations occurring in more than one-third of the participants, likely due to strain on the clinical staff. We planned to explore the effect of these protocol violations by performing a sensitivity analysis of the primary outcome in the per protocol population (i.e. participants without one or more protocol violations) but refrained from this due to the small sample size.

Moreover, we were unable to adhere to the published statistical analysis plan due to the reduced sample size and few patients with events for the binary outcomes or the value zero for the continuous outcomes. Consequently, the results presented in this report are based on a post hoc decision on how to analyse the
data in a sensible manner adhering to the protocol to the extent possible in accordance with the trial statistician.

Perspectives

Several clinical questions remain unanswered regarding the use of corticosteroids in COVID-19, among others the timing of initiation, optimal dosing regime and duration of treatment. In our survey, we found that the dose preferences for corticosteroid use in COVID-19 varied among doctors and that most would enrol their patients into a trial comparing higher versus lower doses of dexamethasone. The doses used in clinical practice also varied between hospitals. Of note, the dose used was often higher than that used in the RECOVERY trial. Consequently, the higher vs. lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial was commenced on August 27, 2020, to provide data on the effect of 12 mg vs. 6 mg of dexamethasone in a similar cohort of patients. In this trial, we also include patients using corticosteroids at the time of screening and patients who have limitations in the use of life-support to increase the generalisability of the results.

Conclusions

In this early terminated randomised clinical trial of adult patients with COVID-19 and severe hypoxia, we were unable to provide any precise estimates on the benefits and harms of hydrocortisone versus placebo for any outcomes as only 3% of the planned sample size had been enrolled. We did learn important lessons that have informed the design and conduct of the COVID STEROID 2 trial.

Acknowledgements

We thank the clinical and research staff at all participating departments, the funding sources, and the regulatory authorities for rapid case handling and approvals. Most importantly, we thank all patients and relatives who have provided consent for participation in the trial.
Conflicts of interest

The Department of Intensive Care, Rigshospitalet, has received funds for other research projects from the Novo Nordisk Foundation, Ferring and Fresenius Kabi. TB reports grants from Novo Nordisk Foundation, grants from Lundbeck Foundation, grants from Simonsen Foundation, grants and personal fees from GSK, grants and personal fees from Pfizer, personal fees from Boehringer Ingelheim, grants and personal fees from Gilead, personal fees from MSD, grants from Kai Hansen Foundation, outside the submitted work. CSU has received personal fees from AstraZeneca, GSK, Chiesi, TEVA, ALK-Abello, Orion Pharma, Boehringer-Ingehelm, Sanofi-Genzyme, Novartis and Actelion outside the submitted work. The Department of Intensive Care Medicine, Bern University Hospital (Inselspital), has or has had research & development/consulting contracts with Edwards Lifesciences Services GmbH, Phagenesis Limited and Nestlé. The money was paid into a departmental fund, and none of the authors received any financial gain. The Department of Intensive Care Medicine, Bern University Hospital (Inselspital), has received unrestricted educational grants from the following organisations for organising bi-annual postgraduate courses in the fields of critical care ultrasound, management of extracorporeal membrane oxygenation (ECMO) and mechanical ventilation: Pierre Fabre Pharma AG (formerly known as RobaPharm), Pfizer AG, Bard Medica SA, Abbott AG, Anandic Medical Systems, PanGas AG Healthcare, Orion Pharma, Bracco, Edwards Lifesciences AG, Hamilton Medical AG, Fresenius Kabi (Schweiz) AG, Getinge Group Maquet AG, Dräger Schweiz AG, and Teleflex Medical GmbH. The remaining authors have no conflicts of interest to declare.
References

1. Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5: 536-44.

2. World Health Organization. Novel Coronavirus(2019-nCoV). Situation Report 22. Available from: https://www.who.int/docs/default-source/Coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2. Accessed on March 18 2020. 11 February 2020.

3. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, Scarlata S, Agro FE. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020; 288: 192-206.

4. Rygard SL, Butler E, Granholm A, Moller MH, Cohen J, Finser P, Perner A, Myburgh J, Venkatesh B, Delaney A. Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2018; 44: 1003-16.

5. Sun S, Liu D, Zhang H, Zhang X, Wan B. Effect of different doses and time-courses of corticosteroid treatment in patients with acute respiratory distress syndrome: A meta-analysis. Exp Ther Med 2019; 18: 4637-44.

6. Ye Z, Wang Y, Colunga-Lozano LE, Prasad M, Tangamornsuksan W, Rochwer B, Yao L, Motaghi S, Couban RJ, Ghadimi M, Bala MM, Gomaa H, Fang F, Xiao Y, Guyatt GH. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ 2020; 192: E756-E67.

7. World Health Organization (WHO). Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. 13. March 2020.

8. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed 01 June 2020.

9. Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Keseioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofante JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020; 46: 854-87.
10. Bhimraj A, Morgan RL, Shumaker AH, Laverne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Muller WJ, O’Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis 2020.

11. Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) (NCT02735707). Available from: https://clinicaltrials.gov/ct2/show/NCT02735707?term=remap+cap&draw=2&rank=1.

12. Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial (NCT04360876). Available form: https://clinicaltrials.gov/ct2/show/NCT04360876?term=COVID+STEROID&draw=2&rank=3.

13. Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia (SMART) (NCT03852537). Available from: https://clinicaltrials.gov/ct2/show/NCT03852537?term=COVID+STEROID&draw=2&rank=4.

14. Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure (NCT04244591). Available from: https://clinicaltrials.gov/ct2/show/NCT04244591?term=COVID+STEROID&draw=2&rank=5.

15. Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm (NCT04355247). Available from: https://clinicaltrials.gov/ct2/show/NCT04355247?term=COVID+STEROID&draw=2&rank=7.

16. Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (MP-C19) (NCT04323592). Available from: https://clinicaltrials.gov/ct2/show/NCT04323592?term=COVID+STEROID&draw=2&rank=13.

17. Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19 (MetCOVID) (NCT04343729). Available from: https://clinicaltrials.gov/ct2/show/NCT04343729?term=COVID+methylprednisolone&draw=2&rank=3.

18. Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 (DEXA-COVID19) (NCT04325061). Available from: https://clinicaltrials.gov/ct2/show/NCT04325061?term=COVID+and+dexa&draw=2&rank=1.

19. Community-Acquired Pneumonia: Evaluation of Corticosteroids (CAPE_COD) (NCT02517489). Available from: https://clinicaltrials.gov/ct2/show/NCT02517489?term=COVID+hydrocortisone&draw=2&rank=5.

20. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T,
Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv 2020: 2020.06.22.20137273.

WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emsberson J, Fisher D, Giraud B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JPT, Horby P, Juni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Moller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 2020; 324: 1330-41.

World Health Organization. Corticosteroids for COVID-19. Living guidance. 2 September 2020.

Petersen MW, Meyhoff TS, Helleberg M, Kjaer MN, Granholm A, Hjortso CJS, Jensen TS, Moller MH, Hjortrup PB, Wetterslev M, Vesterlund GK, Russell L, Jorgensen VL, Tjelle K, Benfield T, Ulrik CS, Andreasen AS, Mohr T, Bestle MH, Poulsen LM, Hitz MF, Hildebrandt T, Knudsen LS, Moller A, Solling CG, Brochner AC, Rasmussen BS, Nielsen H, Christiansen S, Strom T, Cronhjort M, Wahlin RR, Jakob S, Cioccari L, Venkatesh B, Hammond N, Jha V, Myatra SN, Gluud C, Lange T, Perner A. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-Protocol and statistical analysis plan. Acta Anaesthesiol Scand 2020.

World Medical Association. WMA Declaration of Helsinki - Ethical Principles for Medical Research involving Human Subjects. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/20132013/. Accessed on Feb 26, 2020. 2013.

European Medicines Agency. Science Medicines Health. Good Clinical Practice. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-clinical-practice#international-clinical-trials-section. Accessed on March 18 2020.

Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother 2010; 1: 100-7.

Munch MW, Granholm A, Myatra SN, Vijayaraghavan BKT, Cronhjort M, Wahlin RR, Jakob SM, Cioccari L, Kjaer MN, Vesterlund GK, Meyhoff TS, Helleberg M, Moller MH, Benfield T, Venkatesh B, Hammond N, Micallef S, Bassi A, John O, Jha V, Tjelle Kristiansen K, Ulrik CS, Jorgensen VL, Smitt M, Bestle MH, Andreasen AS, Poulsen LM, Rasmussen BS, Brochner AC, Strom T, Moller A, Khan MS, Padmanaban A, Divatia JV, Saseedharan S, Borawake K, Kapadia F, Dixit S, Chawla R, Shukla U, Amin P, Chew MS, Gluud C, Lange T, Perner A. Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19: A Preliminary Report. medRxiv 2020: 2020.06.22.20137273.

This article is protected by copyright. All rights reserved
COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: protocol and statistical analysis plan. Acta Anaesthesiol Scand 2021.

28. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schunemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E, Guyatt GH. Randomized trials stopped early for benefit: a systematic review. JAMA 2005; 294: 2203-9.

29. Granholm A, Munch MW, Myatra SN, Vijayaraghavan BKT, Cronhjort M, Wahlin RR, Jakob SM, Cioccai L, Kjaer MN, Vesterlund GK, Meyhoff TS, Helleberg M, Moller MH, Benfield T, Venkatesh B, Hammond N, Micallef S, Bassi A, John O, Jha V, Kristiansen KT, Ulrik CS, Jorgensen VL, Smitt M, Bestle MH, Andreasen AS, Poulsen LM, Rasmussen BS, Brochner AC, Strom T, Moller A, Khan MS, Padmanaban A, Divatia JV, Saseedharan S, Borawake K, Kapadia F, Dixit S, Chawla R, Shukla U, Amin P, Chew MS, Gluud C, Lange T, Perner A. Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysis. Acta Anaesthesiol Scand 2021.
### Table 1: Baseline characteristics

| Baseline characteristics                  | All patients (n=30) | Hydrocortisone (n=16) | Placebo (n=14) |
|-------------------------------------------|---------------------|------------------------|----------------|
| Median age (IQR) — yrs                    | 61 (53-73)          | 59 (52-74)             | 62 (55-71)     |
| Male sex – no. (%)                        | 24 (80%)            | 14 (88%)               | 10 (71%)       |
| Median weight (IQR) – kg                  | 86 (75-106)         | 85 (76-107)            | 92 (77-106)    |
| Chronic co-morbidities – no. (%)          |                     |                        |                |
| Ischemic heart disease or heart failure   | 1 (3%)              | 1 (6%)                 | 0 (0%)         |
| Hypertension                              | 8 (27%)             | 5 (31%)                | 3 (21%)        |
| Chronic pulmonary disease                 | 5 (17%)             | 2 (13%)                | 3 (21%)        |
| Diabetes mellitus                         | 4 (13%)             | 2 (13%)                | 2 (14%)        |
| Location at enrolment – no. (%)           |                     |                        |                |
| Emergency department or prehospital setting | 0 (0%)              | 0 (0%)                 | 0 (0%)         |
| Hospital ward                             | 8 (27%)             | 5 (31%)                | 3 (21%)        |
| Intermediate care unit                    | 0 (0%)              | 0 (0%)                 | 0 (0%)         |
| Intensive care unit                       | 22 (73%)            | 11 (69%)               | 11 (79%)       |
| Median time from symptom onset to hospital admission (IQR) – days | 6 (3-8) | 7 (5-8) | 6 (0-10) |
| Median time from hospital admission to randomisation (IQR) - days | 4 (1-8) | 4 (1-7) | 6 (1-8) |
| Oxygen supplementation                     |                     |                        |                |
Invasive mechanical ventilation – no. (%)  | 11 (37%) | 5 (31%) | 6 (43%)
---|---|---|---
Median FiO₂ (IQR)  | 49 (40-61) | 55 (45-65) | 47 (38-55)
Median duration (IQR) - hrs  | 14 (5-20) | 6 (4-20) | 15 (13-21)
Non-invasive ventilation or continuous use of CPAP – no. (%)  | 4 (13%) | 2 (13%) | 2 (14%)
Median FiO₂ (IQR)  | 55 (53-66) | 55-55** | 45-100**
Median duration (IQR)- hrs  | 3 (3-22) | 2-3** | 3-78**
Open system ventilation – no. (%)  | 15 (50%) | 9 (56%) | 6 (43%)
Median oxygen flow (IQR) – L/min  | 15 (14-25) | 20 (13-25) | 15 (15-19)
Median PaO₂ prior to randomisation (IQR) – kPa  | 10 (8-12) | 11 (9-11) | 9 (8-12)
Median arterial oxygen saturation prior to randomisation (%) (IQR)  | 95 (92-97) | 95 (92-96) | 95 (92-98)
Use of vasopressors or inotropes – no. (%)  | 10 (33%) | 5 (31%) | 5 (36%)
Use of any renal replacement therapy*– no. (%)  | 1 (3%) | 0 (0%) | 1 (7%)
Median plasma lactate prior to randomisation (IQR) – mmol/L  | 1.4 (1.1-1.8) | 1.5 (1.1-1.8) | 1.4 (1.3-1.8)
Treatment with anti-inflammatory agents – no. (%)  | 0 (0%) | 0 (0%) | 0 (0%)
Treatment with potential anti-viral agents – no. (%)  | 7 (23%) | 3 (19%) | 4 (29%)
Remdesivir  | 5 (17%) | 1 (6%) | 4 (29%)
Hydroxychloroquine  | 1 (3%) | 1 (6%) | 0 (0%)
Lopinavir/ritonavir  | 0 (0%) | 0 (0%) | 0 (0%)
Convalescent plasma  | 2 (7%) | 0 (0%) | 2 (14%)
Other  | 1 (3%) | 1 (6%) | 0 (0%)
Treatment with anti-bacterial agents – no. (%)  | 25 (83%) | 13 (81%) | 12 (86%)

IQR: interquartile range, yrs.: years, no.: number, kg: kilograms, FiO₂: fraction of inspired oxygen, hrs: hours, CPAP: continuous positive airway pressure, PaO₂: partial
pressure of oxygen, kPa: kilopascal, mmol: millimoles, L: liter. * Including days in between intermittent renal replacement therapy. ** Range of values is presented instead of median (IQR) as the group only consists of 2 participants.
Table 2: Trial medication administration and protocol violations

| Trial medication administration                      | Hydrocortisone (n=16) | Placebo (n = 14) |
|------------------------------------------------------|------------------------|-----------------|
| Treatment duration in days, median (IQR)             | 7 (6-7)                | 7 (6-7)         |
| Mode of administration, no. (%)                      |                        |                 |
| Continuous infusion                                  | 10 (63%)               | 10 (71%)        |
| Bolus injections                                     | 4 (25%)                | 3 (21%)         |
| Both used in the intervention period                 | 2 (13%)                | 1 (7%)          |
| Protocol violations                                  |                        |                 |
| Participants who did not receive trial medication at all, no. (%) | 0 (0%)                 | 0 (0%)          |
| Participant with one or more protocol violations*   | 8 (50%)                | 3 (21%)         |
| Less than 50% of planned trial medication volume administered on one or more days, no. (%) | 5 (31%)                | 3 (21%)         |
| Use of open-label steroids, no. (%)**               | 3 (19%)                | 1 (7%)          |

* Concomitant use of open-label corticosteroids during the first 14 days after randomisation or less than 50% of planned trial volume administered on each day in the intervention period.

**2 patients were unblinded after the press-release from the RECOVERY trial and received open-label steroid to complete a steroid course of 10 days; 1 patient received open-label steroid due to an allergic reaction to intravenous immunoglobulin; and 1 patient received open-label steroid as antiemetics.

IQR: interquartile range, no.: number.
Table 3: Outcomes in the ITT-population

| Primary outcome                                                                 | Hydrocortisone | Placebo | Adjusted mean differences or relative risks (95% CI) | p-value |
|--------------------------------------------------------------------------------|----------------|---------|------------------------------------------------------|---------|
| Days alive without life support at day 28, median (IQR)                        | 7 (2-24)       | 10 (3-26) | -1.1 (-9.5 to 7.3)                                   | 0.79*   |
| No. of participants with one or more serious adverse reactions, no./total no. (%) | 1/16 (6%)      | 0/14 (0%) | -                                                    | 1.00**  |
| All-cause mortality at day 28, no./total no. (%)                              | 6/16 (38%)     | 2/14 (14%) | 2.63 (0.74 to 16.03)                                 | 0.19~   |
| All-cause mortality at day 90, no./total no. (%)                              | 7/16 (44%)     | 3/14 (21%) | 2.04 (0.71 to 8.16)                                 | 0.22*   |
| Days alive without life support at day 90, median (IQR)                       | 41 (6-86)      | 72 (52-88) | -14.7 (-40.4 to 10.9)                               | 0.25§   |
| Days alive and out of hospital at day 90, median (IQR)                        | 31 (8-78)      | 53 (42-68) | -6.5 (-29.6 to 16.7)                                | 0.57¥   |

IQR: interquartile range, no.: number.
* Computed using a linear regression adjusted for invasive mechanical ventilation (y/n) and age below 70 (y/n). Supplemented by Wilcoxon rank sum test (p=0.88).
** Computed using Fisher’s exact test.
~Computed using an unadjusted generalised linear model with log link and binomial error distribution. Supplemented by Fisher’s exact test (p=0.23).
≠ Computed using an unadjusted generalised linear model with log link and binomial error distribution. Supplemented by Fisher’s exact test (p=0.26).
§ Computed using a linear regression adjusted for invasive mechanical ventilation (y/n) and age below 70 (y/n). Supplemented by Wilcoxon rank sum test (p=0.40).
¥ Computed using a linear regression adjusted for invasive mechanical ventilation (y/n) and age below 70 (y/n). Supplemented by Wilcoxon rank sum test (p=0.77)

This article is protected by copyright. All rights reserved
### Table 4: Primary outcome in predefined subgroups

| Days alive without life support at day 28, median (IQR) | n | Hydrocortisone, n | Hydrocortisone | Placebo, n | Placebo |
|--------------------------------------------------------|---|------------------|----------------|------------|---------|
| Age                                                    |   |                  |                |            |         |
| < 70 yrs.                                              | 21| 11               | 20 (3-28)      | 10         | 17 (3-26) |
| ≥ 70 yrs.                                              | 9 | 5                | 5 (0-6)        | 4          | 5 (2-12)  |
| Therapeutic agents against COVID-19                    |   |                  |                |            |         |
| Yes                                                    | 7 | 3                | 8 (2-28)¹      | 4          | 4 (3-8)  |
| No                                                     | 23| 13               | 6 (1-23)       | 10         | 18 (4-28) |
| Invasive mechanical ventilation                        |   |                  |                |            |         |
| Yes                                                    | 11| 5                | 14 (5-20)      | 6          | 5 (1-12) |
| No                                                     | 19| 11               | 6 (2-28)       | 8          | 24 (4-28) |
| Shock                                                  |   |                  |                |            |         |
| Yes                                                    | 4 | 3                | 5 (0-14)²      | 1          | 0**     |
| No                                                     | 26| 13               | 8 (2-28)       | 13*        | 14 (3-28) |
| Chronic lung disease                                   |   |                  |                |            |         |
| Yes                                                    | 5 | 2                | 1-1³           | 3          | 4 (3-14)⁵ |
| No                                                     | 25| 14               | 11 (4-27)      | 11         | 19 (2-28) |

We planned to conduct statistical analyses of subgroup differences on the primary outcome in the ITT population, but refrained from this due to the reduced sample size. Instead, descriptive data for each subgroup is reported. We were unable to report data for the subgroup analysis of geographical region as only Danish patients were included in the trial. Detailed definitions of each subgroup are provided in the published trial protocol.²³

IQR: interquartile range, n: number, yrs.: years.

* 1 patient had a missing value of lactate but did not require vasopressors or inotropes at baseline and was consequently placed in the subgroup of no shock.

---

This article is protected by copyright. All rights reserved.
**No IQR is reported as the subgroup consists of only 1 trial participant.

§ Range of values is presented instead of median (IQR) as the subgroup consists of only 2 participants.

♦ Median (range of values) is presented instead of median (IQR) as the subgroup consists of only 3 participants.
Figure 1: Screening, allocation and follow-up

Enrolment

Assessed for eligibility (n=67)

Excluded (n=37; 6 fulfilled 2 criteria)
- Use of systemic corticosteroids (n=13)
- Invasive mechanical ventilation >48 hours prior to screening (n=5)
- Patient for whom the clinical team had decided not to use invasive mechanical ventilation (n=15)
- Informed consent unobtainable (n=4)
- Patient enrolled in other interventional trial prohibiting co-enrolment (n=6)

Randomised (n=30)

Allocation

Allocated to hydrocortisone (n=16)
- Received allocated intervention (n=16)

Allocated to placebo (n=14)
- Received allocated intervention (n=14)

Follow-up

Lost to follow-up (n=0)
Discontinued intervention (n=2)
- Clinical decision in conjunction with coordinating investigator (n=1)
- Withdrew from active therapy (n=1)

Lost to follow-up (n=0)
Discontinued intervention (n=1)
- Withdrew from active therapy (n=1)

Analysis

Analysed (n=16)

Analysed (n=14)